XBIO

Xenetic Biosciences Inc. is a cutting-edge biopharmaceutical firm headquartered in Framingham, Massachusetts, dedicated to revolutionizing cancer treatment through innovative therapies. Leveraging its proprietary XCART platform, the company specializes in the development of personalized chimeric antigen receptor T (CAR T) cell therapies that specifically target unique tumor neoantigens, thereby offering customized treatment solutions for patients. With a robust pipeline and a commitment to addressing critical unmet needs in oncology, Xenetic is poised to emerge as a leader in the dynamic landscape of personalized medicine, driving both efficacy and patient outcomes.